|
WO2016111957A1
|
|
Chloroquinoline triazole compounds, composition and uses
|
|
WO2016085832A1
|
|
Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
|
|
WO2016081292A1
|
|
Host and intestinal microbiota derived metabolomic blood plamsa signature for prior radiation injury
|
|
WO2016073348A1
|
|
Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
|
|
WO2016069549A1
|
|
Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins
|
|
WO2016044096A1
|
|
Repopulation of organs and tissues using a yap-ert2 fusion protein
|
|
WO2016028870A1
|
|
Methods and compositions for assessing germline risk of cancer
|
|
WO2015195458A1
|
|
Therapeutic nanoparticles and methods thereof
|
|
WO2015167948A1
|
|
Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
|
|
WO2015120362A1
|
|
Methods of grading carcinomas
|
|
WO2015094782A1
|
|
B7x and its derivatives for treating and preventing cardiovascular disease
|
|
WO2015073274A1
|
|
Wnt/beta-catenin inhibitor-eluting endovascular stent
|
|
WO2015066001A1
|
|
Nucleic acid-scaffolded small molecule libraries
|
|
US2015105447A1
|
|
Fidgetin-like 2 as a target to enhance wound healing
|
|
WO2015050686A2
|
|
Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
|
|
WO2015038924A1
|
|
Modified paramagnetic nanoparticles for targeted delivery of therapeutics and methods thereof
|
|
US2014363493A1
|
|
LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY
|
|
US2014356354A1
|
|
Therapy for filovirus infection
|
|
WO2014189832A1
|
|
Il-34 receptor assays and uses thereof
|
|
WO2014176498A1
|
|
Method of treating tuberculosis
|
